Comparative Pharmacology
Head-to-head clinical analysis: DARVON COMPOUND 65 versus KESSO GESIC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DARVON COMPOUND 65 versus KESSO GESIC.
DARVON COMPOUND-65 vs KESSO-GESIC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
DARVON COMPOUND-65 contains propoxyphene, a centrally acting opioid agonist with analgesic effects primarily mediated through mu-opioid receptors. Aspirin inhibits cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis. Caffeine is a CNS stimulant with additive analgesic effects.
KESSO-GESIC is a combination analgesic containing butalbital (barbiturate), acetaminophen, and caffeine. Butalbital depresses the CNS by enhancing GABA-A receptor activity, acetaminophen inhibits COX enzymes centrally, and caffeine is a CNS stimulant that may enhance analgesia.
1 capsule (propoxyphene HCl 65 mg, aspirin 389 mg, caffeine 32.4 mg) orally every 4 hours as needed for pain; maximum 6 capsules per day.
Adults: 2 tablets (325 mg acetaminophen + 5 mg hydrocodone per tablet) orally every 4-6 hours as needed for pain; maximum 8 tablets per day.
None Documented
None Documented
Propoxyphene: 6-12 hours (mean 8 h); nordextropropoxyphene: 22-30 hours (accumulates with repeated dosing; risk of toxicity)
Terminal elimination half-life is 2–4 hours in healthy adults. In hepatic impairment, half-life may be prolonged up to 8 hours; in renal impairment, minimal change.
Renal: ~90% as propoxyphene and metabolites (nordextropropoxyphene); biliary/fecal: ~10%
Renal excretion of unchanged drug and metabolites: approximately 60% renal, 40% biliary/fecal. Major metabolites include glucuronide conjugates.
Category C
Category C
Opioid Analgesic Combination
Opioid Analgesic Combination